Welfare reform is possible: we did it before, we can do it again
All sides agree that the costs are unsustainable and we can’t continue to write people off
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Merck's subcutaneous KEYTRUDA QLEX approved in Japan
Merck & Co.'s KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous use has been approved by Japan's Ministry of Health, Labor and Welfare for all indications previously approved for KEYTRUDA. KEYJECT, the planned trademark for KEYTRUDA QLEX in Japan, can be administered in as little